Related by context. All words. (Click for frequent words.) 75 Announces Successful Completion 75 Successfully Completed 74 Announces Commencement 74 Announce Completion 73 Provides Updates 73 Completes Enrollment 73 Provides Update Regarding 73 Receives Notification 72 Completes Patient Enrollment 72 Completes Successful 72 Previously Announced 72 Announces Termination 72 Updates Status 72 Signs Agreements 72 Announces Initiation 72 Board Authorizes 72 Provides Clarification 72 Updates Guidance 72 Secures Financing 72 Significant Increase 72 Announce Receipt 71 Milestone Achieved 71 Announces Signing 71 Announces Cancellation 71 Completes Initial 71 Announce Commencement 71 Provides Operational Update 71 Reports Positive 71 Completes Financing 71 Successfully Completes 71 Announces Publication 71 Closes Sale 71 Obtains Approval 71 Complete Merger 70 Receives NASDAQ 70 Crowflight Announces 70 Subsidiary Signs 70 Receives Conditional Approval 70 Re Affirms 70 Closes Previously Announced 70 Announces Successful 70 Acquire Controlling Interest 70 Results Confirm 70 Announces Completion 70 Receives Milestone Payment 70 Consummates 70 Explore Strategic Alternatives 70 Receives Confirmation 70 Clinical Trial Results 70 Evaluate Strategic Alternatives 70 Has Commenced 70 Receives Approval 70 Files Patent Application 70 Progresses 69 Subsidiary Completes 69 Enters Into Agreement 69 Strengthens Balance Sheet 69 Provides Guidance 69 Significant Milestone 69 Announces Shareholder Approval 69 Successful Launch 69 Presents Positive 69 Net Loss Narrows 69 Announces Resumption 69 Net Loss Widens 69 Present Preclinical Data 69 Finalises 69 Updates Shareholders 69 Achieves Significant 69 Receives Orphan Drug Designation 69 Awarded Contracts 69 Announces Filing 69 Enters Into Definitive Agreement 69 Announces Receipt 69 Mechel Announces 69 Closes Financing 69 1st Quarter Results 69 Q3 Loss Widens 69 Announce License Agreement 69 Announces Stockholder Approval 69 PPD Declares 69 Nears Completion 68 Restructures Debt 68 Key Milestones 68 Completes Installation 68 3rd Quarter Results 68 BIOLASE Announces 68 Significantly Increases 68 Extends Tender Offer 68 Announces Underwriters Exercise 68 Patient Enrollment 68 Commences Phase 68 Signs MOU 68 Commences Operations 68 Mutually Agree 68 Receives Favorable 68 Successfully Concludes 68 Announces Presentation 68 Pending Acquisition 68 Shareholders Approve 68 Terminates Contract 68 Preclinical Data 68 Submits Application 68 Collaborators Present 68 Announces Stock Repurchase 68 Concludes Acquisition 68 Achieves Positive 68 Planned Acquisition 68 Acquire Assets 68 Receives Notice 68 Successfully Tests 68 Meets Primary Endpoint 68 Subsidiary Receives 68 Achieves Milestone 68 Successfully Complete 68 Completes Purchase Of 68 TriCo Bancshares Announces 68 Announces Effective Date 68 Subsidiary Enters 68 Receives Unsolicited 68 Stockholders Approve Merger 68 Finalizes Agreement 68 Significantly Expands 68 Preliminary Results 68 Forges Ahead 68 Announces Intent 68 Fiscal Quarter Results 68 Announce Successful Completion 68 Expands Scope 68 Closes Oversubscribed 68 Profitable Quarter 68 Announces Divestiture 68 Shares Surge 68 Shares Climb 68 Discontinues 68 Initiates Phase 68 Enters Joint Venture 68 Receives Patent 68 Completes Transaction 68 Regains Compliance With 68 Streamlines Operations 68 Signs Option Agreement 68 Issues Clarification 68 Announces Positive 68 Increases Size 68 Phase III Clinical Trial 68 Terminates Merger Agreement 68 Attains 68 Completes Private Placement 68 Doubles Capacity 68 Enters Agreement 68 Jointly Announce 68 Closes Merger 68 Successfully Closes 68 Announces Restatement 68 Regains Compliance 67 Commences Production 67 Announces FDA Clearance 67 Completes Refinancing 67 Announces Favorable 67 Strengthens Its 67 Receives Commitment 67 Files IND 67 Extends Offer 67 ANADIGICS Announces 67 Medoro Resources Announces 67 Commercializes 67 Shareholders Approve Acquisition 67 Exercises Option 67 Has Received 67 Presents Preclinical Data 67 Shares Soar 67 Phase IIb Clinical Trial 67 Increases Stake 67 Announce Merger Agreement 67 Renegotiates 67 Review Initiated 67 Completes Purchase 67 Final Stages 67 Patients Enrolled 67 Phase 2b Clinical Trial 67 Restate Financial 67 Provides Update 67 Important Milestone 67 Reacquires 67 Milestone Payment 67 Flamel Technologies Announces 67 Finalizes Acquisition 67 Q1 Loss Widens 67 Confirms Receipt 67 Receives Certification 67 Completes Second Tranche 67 Expands Capacity 67 Q2 Loss Narrows 67 CFO Resigns 67 Temporarily Suspends 67 Strengthens Presence 67 Extends Expiration Date 67 FY# Loss Widens 67 Commence Trading 67 Receives Conditional 67 DOR BioPharma Announces 67 Increases Ownership 67 Initiates Clinical 67 Secures Contract 67 Receives Positive 67 Q1 Loss Narrows 67 Announces Issuance 67 Increases Capacity 67 Reduces Debt 67 NYMH Announces 67 Acquires Controlling Interest 67 Reconfirms 67 Receives FDA Clearance 67 Proves Successful 67 Completes Tender Offer 67 Drug Candidate 67 Initiates Clinical Trial 67 Completes Drilling 67 Sign License Agreement 67 Medicure Announces 67 Reports Significantly Improved 67 Miraculins Announces 67 Announces Private Placement 67 Shareholders Approve Merger 67 Signs Merger Agreement 67 Announces Repurchase 67 Milestone Reached 67 Announces Operational Update 67 Commence Production 67 Completes Reverse Merger 67 Announces Intention 67 Univest Corporation Declares 67 NDA Submission 67 Successful Conclusion 67 Trading Halt 67 Q4 Loss Widens 67 Receives Funding 67 Settles Litigation 67 Closes Second Tranche 67 Loss Widens 67 SulphCo Announces 67 Amends Agreement 67 Files Shelf Registration Statement 67 Completes Expansion 67 Provides Updated 67 Inks MOU 67 Announces Refinancing 67 Announces Preliminary 67 KEMET Announces 66 Announce Expiration 66 Provides Preliminary 66 Amends Terms 66 Underwriters Exercise 66 XPEL Announces 66 Amend Merger Agreement 66 Completes Merger 66 Expand Collaboration 66 Confirms Significant 66 Enters Into Joint Venture 66 Enhance Shareholder Value 66 Seeks Approval 66 Begins Drilling 66 Phase III Trial 66 Further Strengthens 66 Phase IIb Trial 66 Jumps Higher 66 Q3 Loss Narrows 66 Migraine Drug 66 Lupus Drug 66 Annual Meeting Date 66 Q2 Loss Widens 66 Completes 66 Significantly Expand 66 Spectrum Pharmaceuticals Announces 66 Expands Portfolio 66 Extends Term 66 L.P. Announces 66 Underwritten Public 66 Cash Tender Offers 66 Phase 1b Clinical Trial 66 Fully Subscribed 66 CGGVeritas Announces 66 Successfully Completes Tender Offer 66 Initiates Phase II 66 Extends Maturity 66 Announcement Regarding 66 Q4 Loss Narrows 66 Releases Second Quarter 66 Announces Expanded 66 Posts Wider Loss 66 Accelerates Growth 66 Gets Approval 66 Provides Shareholder 66 Improves Survival 66 Enters Negotiations 66 Becomes Effective 66 Commences Tender Offer 66 Flagstone Re Announces 66 Share Repurchases 66 Reduces Risk 66 FDA Clears 66 Initiates Phase III 66 Announces Organizational Changes 66 Signs Joint Venture 66 Integra LifeSciences Announces 66 Receives Approvals 66 Announces Revised 66 Awarded Patent 66 Receives Notice Regarding 66 Executes Agreement 66 Stereotaxis Announces 66 Voluntarily Withdraw 66 Announce Joint Venture 66 Its Previously Announced 66 Receives Regulatory 66 Secures Additional 66 Completes Restructuring 66 Expands Capabilities 66 Lorus Therapeutics Announces 66 Initiates Enrollment 66 Buyout Offer 66 Anworth Announces 66 HSR Waiting Period 66 Regains NASDAQ 66 Announces Debt Settlement 66 Projected Release Date 66 Announce Signing 66 Grants Options 66 Closes Private Placement 66 Recommence 66 Pharmaceuticals Initiates 66 Directors Authorizes 66 Completes Integration 66 Achieves Record 66 Maintains Strong 66 Signs Licensing Agreement 66 Completes Divestiture 66 Strengthens Leadership 66 2nd Quarter Results 66 Monetizes 66 Strengthens Position 65 Losses Narrow 65 Extends Collaboration 65 Announces Upcoming 65 Signs LOI 65 Announce Agreement 65 Successfully Demonstrates 65 First Patient Treated 65 Total Knee Arthroplasty 65 Announces Expansion 65 Undertakes 65 Announces Definitive Agreement 65 Awarded Patents 65 Contracts Awarded 65 Announces Dismissal 65 EastGroup Properties Announces 65 Receives CE Marking 65 Reports Receipt 65 Signs Purchase Agreement 65 Formalizes 65 Submits NDA 65 Enters Into Definitive 65 Completes Previously Announced 65 Announce Collaboration Agreement 65 Closes Acquisition Of 65 Announces Profitable 65 Asset Swap 65 Equity Funds Declare 65 Fortifies 65 Announces Proposed 65 Largest Shareholder 65 Warrants Exercised 65 Celebrates Successful 65 Revises Guidance 65 Board Unanimously Rejects 65 Forecast Quick Facts 65 Nine Month 65 Clinical Trial Evaluating 65 Shares Plunge 65 Phase 2a Trial 65 Anounces 65 Repositions 65 Announces Share Repurchase 65 Commences 65 Patent Issued 65 Announces Webcast 65 Announces Postponement 65 More Than Doubled 65 Expand Scope 65 Moves Towards 65 Private Placement Closed 65 Enters Into Negotiations 65 Enters Into Licensing Agreement 65 Stock Soars 65 Option Grants 65 IND Filing 65 Establish Joint Venture 65 Affirms Commitment 65 Completes Sale Of 65 Jointly Develop 65 Shareholder Meeting Date 65 Previously Announced Private Placement 65 Posts Strong 65 Pacific Rubiales Announces 65 Drilling Permit 65 Takes Delivery 65 Reaffirms Guidance 65 Study Evaluating 65 Receives Notice From 65 Confirmatory Phase 65 Poniard Pharmaceuticals Announces 65 Wins Approval 65 Virco Announces 65 Mln Shares 65 Debt Refinancing 65 Single Dose 65 Inks Pact 65 Successfully Delivers 65 Reiterates Fiscal 65 Shares Plummet 65 Oceaneering Announces 65 Successfully Completes Phase 65 Entry Into 65 Nasdaq Delisting Notice 65 Announces Licensing Agreement 65 Spins Off 65 Announces Non Brokered 65 Sign Licensing Agreement 65 Discloses 65 Clarifies Status 65 Wins Contract 65 Positive Results 65 Largest Ever 65 Pivotal Trials 65 Receives Shareholder Approval 65 Announces Granting 65 Reactivates 65 &Amp; 65 Study Indicates 65 Acquire Stake 65 Subsidiary Acquires 65 Begins Shipment 65 Increases Guidance 65 Enters Into Exclusive 65 Approve Merger 65 Successfully Launches 65 Cash Flow Positive 65 Completes Reorganization 65 Receives Favorable Ruling 65 Signs Pact 65 Guidance Quick Facts 65 Dividend Payment 65 Finalize Agreement 65 Announces Closing 65 Nasdaq Notice Regarding 65 Marks Milestone 65 Equity Stake 65 Opinions Requested 65 NASDAQ Listing Requirements 65 Announce Collaboration 65 Receives Clearance 65 Completes Sale 65 Releases Third Quarter 65 Share Buyback Program 65 Lowers Guidance 65 Announces Departure 65 Establishes Joint Venture 65 Initiate Phase III 65 Diversifies 65 Completes Transition 65 Hythiam Announces 65 Approves Share Repurchase 65 Terminates Agreement 65 Phase 2b Trial 65 Nasdaq Listing Requirements 65 Signs Definitive 65 First Patient Enrolled 65 Pivotal Study 65 Announces Definitive Agreements 65 Sign Definitive Agreement 65 Announces Additions 65 Completes Conversion 65 Acquires Remaining 65 Bulk Sampling Program 65 Flexpoint Announces 65 Announces Cash Dividend 65 Files Annual Report 65 Acquire Controlling Stake 65 Rapid Expansion 65 Quadruples 65 Reduces Size 64 Authorizes Additional 64 Upcoming Deadline 64 Sign Pact 64 Lowest Level 64 Files Voluntary 64 Announces Recapitalization 64 Closes Acquisition 64 Hana Mining Announces 64 Announce Merger 64 Sweetens Bid 64 Reveals Positive 64 Shares Tumble 64 Results Indicate 64 Reports Profitable 64 Drilling Underway 64 Terminate Merger 64 Upcoming Conferences 64 Posts Loss 64 Mln Common 64 Completes Acquisitions 64 Achieves Unprecedented 64 Commences Trading 64 InterOil Announces 64 Announce Initiation 64 Unsolicited Tender Offer 64 ARRIS Announces 64 Announce Definitive Agreement 64 Completes Due Diligence 64 Restructures 64 Significant Milestones 64 Measurement Specialties Announces 64 Temporary Shutdown 64 Significantly Improves 64 Loss Narrows 64 Declares Increase 64 Amends Credit 64 Loss Widens Quick Facts 64 Redeems 64 Receives Order 64 Shows Promising 64 Terminates 64 Proxy Proposals 64 Announce Early Termination 64 Proposed Offering 64 Achieves Prestigious 64 Voluntarily Delist 64 Demonstrates Commitment 64 Enlarges 64 ViRexx Announces 64 Stake Sale 64 Secures Funding 64 Commences Exploration 64 Terminate Merger Agreement 64 Demonstrates Positive 64 Pivotal Trial 64 Signs License Agreement 64 KB Home Swings 64 Fifth Consecutive 64 Acquire Remaining 64 Enters Into License Agreement 64 Issues Guidance 64 Robust Growth 64 Receives Positive Results 64 Obtains License 64 Completes Acquisition 64 Commence Phase 64 Expand Capacity 64 Widens Quick Facts 64 Recommences 64 Achieves Profitability 64 Record Third Quarter 64 Anti Tumor Activity 64 Announces Record Date 64 Receives Requisite Consents 64 Enters Into 64 Submits Biologics License Application 64 Remains Committed 64 Revenues Increase 64 Reminds Shareholders 64 Files Shelf Registration 64 Discuss Third Quarter 64 Announces Expiration 64 Q2 Profit Declines 64 Announces Redemption 64 Achieves Record Sales 64 Begins Shipping 64 Signs MoU 64 Legal Dispute 64 Sees Positive 64 Takeover Talks 64 Commence Immediately 64 Significantly Reduces 64 Shares Slump 64 Initiates 64 Further Validates 64 Has Been Awarded 64 Results Exceed Expectations 64 Closes Buyout 64 View Quick Facts 64 Q2 Profit Rises 64 Achieves ISO # 64 Share Buyback 64 Pending Litigation 64 Enters Into Merger Agreement 64 Finalizes Purchase 64 Shows Promise 64 Signs Memorandum 64 Completes Merger With 64 Dividend Announcement 64 Finalizes 64 Nearing Completion 64 Continues Momentum 64 FDA Approvals 64 Initiates Clinical Trials 64 Q4 Profit Declines 64 More Than Doubles 64 Being Studied 64 Technip Awarded Contract 64 Enters Into Agreements 64 Beat Estimates 64 Restructure Debt 64 Signs Definitive Agreement 64 Record Fourth Quarter 64 Expansion Into 64 Immunomedics Announces 64 Submits Proposal 64 Furthers 64 Files Definitive Proxy 64 Proxy Contest 64 Pending Merger 64 Resolves Dispute 64 Positions Itself 64 Adopts Shareholder Rights 64 WorldHeart Announces 64 Exceeds Expectations 64 FEED Contract 64 4Q Loss Widens 64 Obtains Exclusive License 64 Signs Definitive Agreements 64 Merger Discussions 64 Nasdaq Deficiency Notice 64 Resolve Dispute 64 Arranges Private Placement 64 Joins OTCQX 64 Receives Orphan Drug 64 Obtains Patent 64 Increases Quarterly 64 Eighth Consecutive 64 BioSante Pharmaceuticals Announces 64 Demonstrates Significant 64 Receives Approvable Letter 64 Announces License Agreement 64 Agreement Reached 63 Increases Private Placement 63 Secures Long Term 63 Drilling Update 63 Stockholder Vote 63 Prolongs Survival 63 Q4 Profit Rises 63 Q4 Profit Plunges 63 Successfully Tested 63 Stockholders Approve 63 Receives Delisting Notice 63 Awaits Approval 63 Multi Billion Dollar 63 FDA Accepts 63 Delist From 63 Finalizes Sale Of 63 Comprehensive Overview 63 Review Strategic Alternatives 63 Oral Calcitonin 63 Arbitration Proceedings 63 Announces Proposed Acquisition 63 Delays Filing 63 Patent Covering 63 Enter Into 63 Identifies Potential 63 Dia Bras Announces 63 Announces Formation 63 Outlook Quick Facts 63 Aquires 63 Shareholders Approve Increase 63 Announce Shareholder Approval 63 VIVUS Announces 63 Enters Into Strategic 63 Q1 Profit Declines 63 Completes Redemption 63 Up Sharply 63 Regain Compliance 63 Completes Asset 63 Backs FY# Outlook 63 Submits 63 Q1 Adj 63 Commences Initial 63 Q1 Profit Surges 63 Announces Dividend 63 Sells Stake 63 IIROC Resume 63 Expand Relationship 63 PDL BioPharma Announces 63 Confirms Commitment 63 Seek Shareholder Approval 63 Q1 Profit Plunges 63 Settle Litigation 63 Receives Fast Track 63 Regains Nasdaq 63 Demonstrates Ability 63 Momentum Continues 63 Has Entered 63 Resumes Drilling 63 Unveils Latest 63 Confirms Guidance 63 Host Fourth Quarter 63 Announce Intention 63 Completes Dosing 63 Remain Suspended 63 Q1 Profit Rises 63 Receives ISO #:# [002] 63 Winmark Corporation Announces 63 Presses Ahead 63 Expects Higher 63 Cites Positive 63 Preliminary Fourth Quarter 63 Sono Tek Announces 63 Initiates Drilling 63 Signs Lease 63 Q3 Profit Surges 63 Expand Into 63 Nordson Corporation Declares 63 Raises Stake 63 Delineates 63 Revises Fourth Quarter 63 Enrolls First 63 Vertex Pharmaceuticals Announces 63 Improved Margins 63 Unsolicited Proposal From 63 Fancamp Announces 63 Merger Talks 63 Introduces Next Generation 63 Acquires Assets 63 Patents Issued 63 Granted Orphan Drug 63 Sells Portion 63 Regains Full 63 GeoMet Announces 63 Patent Infringement Litigation 63 Announces Normal Course 63 Slightly Lower 63 Webcast Discussion 63 Successfully Deploys 63 Increases Quarterly Cash Dividend 63 Provides Detailed 63 FY# Loss Narrows 63 Shareholder Approval 63 Wizzard Software Announces 63 Starts Drilling 63 Files Registration Statement 63 #.#/Share [002] 63 Announces Adjournment 63 Holds Successful 63 Completes Non Brokered 63 Proven Effective 63 Assumes Role 63 Expands Presence 63 Sinks Lower 63 Posts Profit 63 Restructures Operations 63 Study Shows Benefits 63 Awarded Contract 63 Obtains Financing 63 Restate Certain 63 Contract Modification 63 Dose Ranging Study 63 Loss Narrows Quick Facts 63 Buyout Bid 63 Kaydon Corporation Announces 63 Accelerate Commercialization 63 Continued Listing 63 Continues Expansion 63 Narrows Loss 63 Explores Strategic Alternatives 63 Update9 63 Exploring Strategic Alternatives 63 Vantex Completes 63 Increase Stake 63 Unsolicited Proposal 63 Ink Pact 63 Ramco Gershenson Announces 63 4Q Loss 63 Announces Resignation 63 Misonix Announces 63 Submits Revised 63 Moves Forward 63 Commence Drilling 63 Announces Acquisition 63 Trial Evaluating 63 Earnings Decline 63 Receive Milestone Payment 63 Patients Treated 63 Expansion Plans 63 Signs Binding Agreement 63 FY# Guidance 63 Generates Record 63 Overallotment Option 63 Host Teleconference 63 Initial Assay Results 63 News Unternehmensnachrichten 63 Reaches Settlement Agreement 63 Provides Comprehensive 63 Announces Rebranding 63 Expand Presence 63 Reaches Agreement 63 Resumes Production 63 Profit Doubles 63 Sharply Higher 63 Lifts FY# Outlook 63 Recommends Acceptance 63 Q3 Profit Declines 63 Wholly Owned Subsidiary 63 Announces Reverse Split 63 Identifies Key 63 Acquire Majority 63 Increases Share Repurchase 63 Study Showed 63 Rejects Unsolicited 63 Delayed Filing 63 Declares Increased 63 Private Placement Financing 63 Amends Merger Agreement 63 STERIS Corporation Announces 63 Platform Enables 63 Files Preliminary Proxy 63 Q4 Profit Surges 63 Commences Phase III 63 Above Estimates 63 Cuts Costs 63 Secures Patent 63 Introduces Revolutionary 63 Slightly Higher 63 Subsidiary Awarded 63 Licensing Pact 63 Commences Subsequent 63 Files Amended 63 Pharmacyclics Announces 63 Continues Aggressive 63 Develop Novel 63 Successfully Launched 63 Boosts Buyback 63 Announcement acc 63 Revises Third Quarter 63 Subsidiary Expands 63 Being Evaluated 63 Posts Solid 63 Announces Immediate Availability 63 Moves Ahead 63 Receives Permit 62 Newmont Declares Regular 62 NMT Medical Announces 62 Files Restated 62 Enters Final 62 Patent Infringement Suit Against 62 Patient Accrual 62 Restate Financials 62 Forms Joint Venture 62 Profitable Second Quarter 62 Pivotal Phase III 62 Makes Strides 62 Record Levels 62 Revises FY# Outlook 62 Announces Bought Deal 62 Internationally Recognized 62 Has Entered Into 62 Successfully Implemented 62 Expands Relationship 62 Waiting Period 62 TOP Ships Announces 62 Additional Assay Results 62 Raises Dividend 62 Obtains 62 Ducommun Incorporated Announces 62 Reaffirms Commitment 62 Analyst Downgrade 62 Dose Ranging 62 Announces Stock Buyback 62 Receives Recognition 62 Completes Recapitalization 62 Announces Mailing 62 Announces Enhancements 62 Raises Guidance 62 TriMas Corporation Announces 62 Organizational Changes 62 Pays Dividend 62 Commences Consent Solicitation 62 Receives SFDA Approval 62 Lung Cancer Trial 62 Above Consensus 62 Posts Narrower Loss 62 Restates 62 Receives Accreditation 62 Awarded Prestigious 62 Fluor Awarded 62 Shareholder Update 62 Audited Financials 62 Nuvelo Announces 62 Ups Stake 62 Swings To 62 Q3 Profit Rises 62 Director Shareholding 62 Discuss Second Quarter 62 Signs LoI 62 Realigns 62 Annouces 62 Announces Share Buyback 62 Ink Deal 62 Unifies 62 Host Third Quarter 62 Submits Response 62 Receives Authorization 62 Announces Tender Offer 62 Final Spacewalk 62 Survival Benefit 62 Presents Positive Preclinical 62 Registration Statement Declared Effective 62 Improves Efficiency 62 Reveals Receipt 62 Expansion Continues 62 Q2 Adj 62 Carries Out 62 Develop Next Generation 62 BioElectronics Announces 62 Withdraws Proposal 62 Losses Widen 62 Oroco Announces 62 Signs Definitive Merger Agreement 62 Record Second Quarter 62 Subsidiary Enters Into 62 Finalizes Sale 62 Patent Infringement Lawsuit Against 62 Net Profit Jumps 62 Taro Receives 62 Has Doubled 62 Makes Significant 62 Quarterly Dividend Payment 62 Concludes Successful 62 Boosts Stake 62 Announces Conditional Approval 62 SABESP Announces 62 HCV Protease Inhibitor 62 WGNB Corp. Announces 62 Expands Scientific Advisory 62 Doubles Size 62 Plummets 62 Completes Patient Enrolment 62 Unveils Expanded 62 BayStreet.ca Research Alert 62 Pave Way 62 Profit Drops 62 JAK2 Inhibitor 62 #.#.# Meldung [001] 62 IND Application 62 Inks LOI 62 Provides Operational 62 Announces Timing 62 Report Examines 62 PremierWest Bancorp Announces 62 Extends Reach 62 LightPath Technologies Announces 62 Profit Declines 62 Increases Presence 62 Hold Fourth Quarter 62 Combination Treatment 62 Posts Lower 62 Taglich Brothers Initiates Coverage 62 Sees Continued 62 Ticker Symbol Change 62 Introduces Enhanced 62 Contracts Totaling 62 Schweitzer Mauduit Announces 62 Delist 62 Gain Traction 62 Bladex Announces 62 Increases Risk 62 Nasdaq Minimum Bid 62 Strengthen Balance Sheet 62 Debt Tender Offers 62 Achieves ISO 62 Assay Results From 62 Recommends Approval 62 Distribution Pact 62 Q3 Profit Plunges 62 Amplifies 62 Accredits 62 Improves Outcomes 62 Refinances Debt 62 Acquire Remaining Shares 62 Have Been Added 62 Polysilicon Supply Agreement 62 Targets Identified 62 Celebrates Opening 62 Distribution Agreements 62 Regulatory Approvals 62 Submits Bid 62 Guides Q4 62 Lower Than Expected 62 Ground Breaking 62 4Q Loss Narrows 62 Gastar Exploration Announces